CITIUS ONCOLOGY, INC.

Citius Oncology, Inc. announced positive health-related quality of life (HRQoL) results from its pivotal Study 302 of LYMPHIR® (denileukin diftitox-cxdl) in adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). The data, presented at the EORTC-CLTG 2026 Annual Meeting, showed that patients who responded to LYMPHIR reported sustained improvements in skin-related quality of life measures, including reduced symptoms and improved emotional well-being. Additionally, a significant portion of heavily pretreated patients experienced a meaningful decrease in itch. These findings underscore the importance of quality of life considerations in CTCL treatment.

Citius Oncology, Inc. expanded its Board of Directors to nine members and appointed Jonathan Peri, Ph.D., J.D., as an independent Class I director, effective August 10, 2026. Dr. Peri brings extensive leadership experience from higher education, financial services, law, and corporate governance, including serving as President of Manor College and lead advisory board director of First State Bank. His appointment is expected to strengthen the Board's legal, regulatory, and financial oversight as the company focuses on the commercial launch of LYMPHIR.

Citius Oncology, Inc. announced strong commercial momentum for its cancer treatment, LYMPHIR. New institutional accounts ordering LYMPHIR increased by 78% quarter over quarter, and total institutional vial orders rose 31% during the quarter ended June 30, 2026. The company also reported near-universal payer coverage and an estimated initial market for LYMPHIR in cutaneous T-cell lymphoma (CTCL) exceeding $400 million.

Citius Oncology, Inc. announced the presentation of Phase 1 clinical data for LYMPHIR (denileukin diftitox-cxdl) in combination with pembrolizumab in recurrent or refractory gynecologic malignancies at the ASCO Annual Meeting. The investigator-initiated study demonstrated durable responses and manageable tolerability, with a 24% Overall Response Rate (ORR) and a median Progression-Free Survival (mPFS) of 20.5 months for patients achieving clinical benefit. Encouraging signals were observed in heavily pre-treated patients, including those previously treated with immune checkpoint inhibitors. A Phase 2 expansion study is planned.

Citius Oncology reported net product revenues of $1.7 million for the second quarter of fiscal 2026 and $5.6 million for the first half, driven by the LYMPHIR launch. The company secured up to $36.5 million in debt and equity financing post-quarter end to support commercial expansion. Despite strong market access for LYMPHIR with 83% of target accounts on formulary and near 100% payer coverage, the company recorded a net loss of $26.6 million for the quarter, primarily due to a $19.7 million CMO contract cancellation charge.

Citius Oncology, Inc. reported a net loss of $32.1 million for the six months ended March 31, 2026, with revenues of $5.6 million, marking its first revenue generation from LYMPHIR. The company faces substantial doubt about its ability to continue as a going concern due to a negative working capital of $29.4 million and limited cash. To address this, Citius Oncology recently secured $11.5 million from warrant exercises and an initial $10.0 million from a new $25.0 million loan facility.

Citius Oncology, Inc. announced securing up to $36.5 million in new capital through a senior secured term loan credit facility and a warrant inducement transaction. The credit facility from Avenue Capital Group provides up to $25 million, with an initial $10 million funded at closing. Concurrently, the company received approximately $11.5 million from the immediate exercise of existing warrants by a healthcare-focused institutional investor, who was issued new warrants as an inducement. The funds are intended to accelerate LYMPHIR commercialization and support general corporate purposes.

Citius Oncology, Inc. announced the initial shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe through one of its regional distribution partners. This marks a strategic milestone in expanding international patient access to the therapy via Named Patient Programs, complementing the ongoing U.S. commercial launch. The company continues to see encouraging adoption in the U.S. market, which is estimated to exceed $400 million and is underserved by existing therapies.

Citius Oncology, Inc. received a notice from Nasdaq on April 22, 2026, indicating non-compliance with the minimum $1.00 bid price requirement for continued listing. The company's common stock traded below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). CTOR has 180 calendar days, until October 19, 2026, to regain compliance by having its stock close at $1.00 or more for at least ten consecutive business days. The notice does not immediately affect the stock's listing, and the company is evaluating its options.